


Characteristic & Category levels & Switch proportion & P-value\\
\hline
 & PCV7 vs NoVax & 66.7\% & \\
\cline{2-3}
 & PCV10 vs NoVax & 75.0\% & \\
\cline{2-3}
 & PCV13 vs NoVax & 62.5\% & \\
\cline{2-3}
\multirow[t]{-4}{*}{\raggedright\arraybackslash Type of comparison} & PCV13 vs PCV10 & 36.8\% & \multirow[t]{-4}{*}{\raggedleft\arraybackslash 0.021}\\
\cline{1-4}
 & Low & 78.6\% & \\
\cline{2-3}
 & Lower-middle & 80.0\% & \\
\cline{2-3}
\multirow[t]{-3}{*}{\raggedright\arraybackslash Income group} & Upper-middle & 60.6\% & \multirow[t]{-3}{*}{\raggedleft\arraybackslash 0.086}\\
\cline{1-4}
 & Excluded & 71.3\% & \\
\cline{2-3}
\multirow[t]{-2}{*}{\raggedright\arraybackslash Herd effects} & Included & 51.0\% & \multirow[t]{-2}{*}{\raggedleft\arraybackslash 0.013}\\
\cline{1-4}
 & Excluded & 65.8\% & \\
\cline{2-3}
\multirow[t]{-2}{*}{\raggedright\arraybackslash Serotype replacement} & Included & 63.6\% & \multirow[t]{-2}{*}{\raggedleft\arraybackslash 0.815}\\
\cline{1-4}
 & Healthcare/payer & 68.5\% & \\
\cline{2-3}
\multirow[t]{-2}{*}{\raggedright\arraybackslash Study perspective} & Societal & 62.0\% & \multirow[t]{-2}{*}{\raggedleft\arraybackslash 0.421}\\
\hline

